The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Olaratumab Plus Doxorubicin in Advanced Soft Tissue Sarcoma

William D. Tap, MD
Published Online: 11:21 PM, Fri November 6, 2015

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.

This study looked at the combination of olaratumab and doxorubicin compared with doxorubicin alone as treatment for patients with advanced soft tissue sarcoma. The combination showed a 50% improvement in progression-free survival and an 11.8-month increase in overall survival.

Based on this study, the monoclonal antibody is being investigated in an ongoing phase III study and has received an FDA Breakthrough Therapy Designation.

Read more about the study >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.